Back to search

Switzerland· 58711002

Toctino 30 mg, Weichkapseln

A alitretinoin product containing alitretinoinum, registered in Switzerland by GlaxoSmithKline AG and dispensed under Swissmedic category A, on the national reimbursement list. The same ATC class is registered in 8 of our 19 countries.

Reimbursed in Switzerland (BAG SL)Cat A (Swissmedic)ATC D11AH04

Checked against Swissmedic (Switzerland) on

Informational only — not a medical device.

SOURCE REGISTER · CHSwissmedic (Switzerland)normalisedToctino 30 mg, WeichkapselnATCD11AH04REGISTER NO.58711002PACKS LISTED1CHECKEDSeptember 12, 2026

Where it is registered

Alitretinoin is registered in 8 of 19 countries.

Countries holding a registration under ATC D11AH04 (alitretinoin), each read from that country’s own register.

  • This record: Switzerland, from Swissmedic (Switzerland)
  • 5 of them publish a price we can compare per daily dose

Alitretinoin · ATC D11AH04

8 / 19 countries

  • Belgiumprice
  • Canada
  • Denmark
  • Finlandprice
  • Netherlands
  • Norwayprice
  • Switzerlandprice
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of alitretinoin costs, country by country.

Normalised to the WHO defined daily dose (20 mg), so markets compare like for like.

  • Switzerland: $17.29 per daily dose (median across products in the class)
  • Public list prices, converted to USD at the rate date shown

Alitretinoin · price per daily dose (20 mg)

USD · FX 28 Sept 2026

  • CH Switzerland$17.29
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

Swissmedic (Switzerland)
Active substance
alitretinoinum
Manufacturer
GlaxoSmithKline AG
Country
Switzerland (CH)
ATC code
D11AH04
ATC class
Alitretinoin
Defined daily dose
20 mg, O
Swissmedic category
A
Reimbursed
Yes
Source register
Swissmedic (Switzerland)
Last checked
September 12, 2026

Packs & prices · 1

1 priced
  • gtin
    7680587110021
    30 Stk
    CHF 216.5

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Interactions

5 interactions on record for alitretinoin.

Graded by severity as the source publishes them — 1 severe. Severity grades are free for everyone; mechanism and management come with Growth.

  • Severity for every pair — free, no plan needed
  • The source, licence and sync date on every record
  • Mechanism and what to do for each pair — Growth plan

Alitretinoin · interactions on record

5 records

  • 1 severe
  • 4 moderate

Most severe, free to view

  • Aminolevulinic acidL01XD04severe
  • Salicylic acidD01AE12moderate
  • Porfimer sodiumL01XD01moderate
  • MethoxsalenL01XD10moderate
  • Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Mechanism and what to do, in the interaction check
Source: DDInter 2.0 · synced 29 Sept 2026. Grades as the source publishes them.

Same medicine, other countries

Alitretinoin in 12 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All alitretinoin products

Authorised across Europe · EMA

The same active substance is authorised in 14 EEA countries. Names it is sold under:

  • Austria · Alitretan, Toctino
  • Belgium · Alitretinoin Orifarm
  • Germany · Alitrederm, Toctino
  • Denmark · Alitretinoin Orifarm, Toctino
  • Spain · Alitretinoína Ifc, Toctino
  • Finland · Alitretinoin Orifarm, Toctino
  • France · Alizem, Toctino
  • United Kingdom (Northern Ireland) · Alitretinoin Ennogen Healthcare, Alitretinoin Ennogen Ip
  • Italy · Alitrecare, Toctino
  • Netherlands · Alipalmtin, Alitretinoïne Ifc
  • Norway · Alitretinoin Orifarm, Toctino
  • Portugal · Alitretinoína Cantabria
  • Sweden · Alitretinoin Orifarm
  • Slovenia · Toctino

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/cb6fb0d3-80f7-45d1-991f-5a92f7988ca7
GET /v1/drugs/cb6fb0d3-80f7-45d1-991f-5a92f7988ca7?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "unit": null,
  "strength": "alitretinoinum 30 mg",
  "valid_from": "2009-12-01",
  "limitations": "[{\"description\":\"TOCTINO ist indiziert bei Erwachsenen mit schwerem, therapie-refraktärem Handekzem, welches seit mehr als 3 Monaten besteht und auf eine ausgebaute (mindestens 4 Wochen dauernde) topische Behandlung mit potenten Steroiden nicht angesprochen hat. Die Vorbehandlung schliesst die Vermeidung von Kontakten mit der auslösenden Noxe und Hautschutz mit ein.<br>\\nDie Behandlung sollte abgebrochen werden:<br>\\na) wenn sich das Ekzem zufriedenstellend gebessert hat,<br>\\nb) wenn der Patient nach den ersten 12 Wochen immer noch schwere Symptome hat,<br>\\nc) wenn sich das Ekzem nach 24 Wochen nicht wesentlich gebessert hat.<br>\\nTOCTINO darf nur von Dermatologen verschrieben werden.<br>\\n<br>\",\"costApproval\":null,\"isNew\":false,\"limitationCode\":null,\"priceModel\":null,\"validFrom\":\"2009-12-01\"}]",
  "galenic_form": "Kaps 30 mg",
  "therapeutic_area": null,
  "sl_inclusion_date": "2009-12-01",
  "self_retention_pct": 10
}

See everything about alitretinoin.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.